Re-evaluating the Inhibition of Stress Erosions (REVISE): a protocol for pilot randomized controlled trial

Waleed Alhazzani, Gordon Guyatt, John C Marshall, Richard Hall, John Muscedere, Francois Lauzier, Lehana Thabane, Mohammed Alshahrani, Shane W English, Yaseen M Arabi, Adam M Deane, Tim Karachi, Bram Rochwerg, Simon Finfer, Nick Daneman, Nicole Zytaruk, Diane Heel-Ansdell, Deborah Cook, On Behalf Of, Waleed Alhazzani, Gordon Guyatt, John C Marshall, Richard Hall, John Muscedere, Francois Lauzier, Lehana Thabane, Mohammed Alshahrani, Shane W English, Yaseen M Arabi, Adam M Deane, Tim Karachi, Bram Rochwerg, Simon Finfer, Nick Daneman, Nicole Zytaruk, Diane Heel-Ansdell, Deborah Cook, On Behalf Of

Abstract

Introduction: Clinicians routinely administer stress ulcer prophylaxis to mechanically ventilated patients in the intensive care unit (ICU), most commonly prescribing proton pump inhibitors (PPIs). However, the incidence of gastrointestinal (GI) bleeding from stress ulceration is low and recent observational studies suggest these agents may increase infections. Therefore, a large randomized clinical trial (RCT) is needed to inform modern practice. The aim of this multicenter pilot trial is to determine the feasibility of performing a large RCT to investigate the efficacy and safety of withholding intravenous pantoprazole.

Methods and analysis: We will include adult critically ill patients who have an anticipated duration of ventilation of >=48 hours. We will exclude patients with acute or recent GI bleeding, pregnancy, dual antiplatelet therapy, poor prognosis or intent to withdraw life support, or previous enrolment in this or a confounding trial. Following informed consent, patients will be randomized to receive the intervention of placebo (0.9% NaCl) or intravenous pantoprazole 40 mg daily. Patients, families, clinicians, data collectors, adjudicators of outcome and statisticians will be blind to allocation. The three primary feasibility outcomes are the informed consent rate, recruitment rate, and protocol adherence. Clinical outcomes include clinically important upper GI bleeding, ventilator-associated pneumonia (VAP), Clostridium difficile infection, length of stay and mortality in ICU and hospital.

Ethics and approval: This study has been approved by Health Canada, and research ethics board (REB) at each of the participating centers.

Trial registration number: This trial was registered on 31 October 2014. The trial registration number is NCT02290327.

Funding: REVISE Pilot Trial is funded by Research Grant awarded by Physicians Services Incorporated, Dammam University Research Funds, Capital Health Authority Research Award Halifax, and Royal Adelaide Hospital Project Committee Grant.

Conflict of interest statement

Competing interests

Authors have no conflict of interest to declare.

References

    1. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 1999;56(4):347–79.
    1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine. 2013;41(2):580–637.
    1. Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001;5(6):368–75.
    1. Alhazzani W, Alshahrani M, Moayyedi P, Jaeschke R. Stress ulcer prophylaxis in critically ill patients: review of the evidence. Polskie Archiwum Medycyny Wewnetrznej. 2012;122(3):107–14.
    1. Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Critical Care Medicine. 2010;38(11):2222–8.
    1. Lam NP, Le PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Critical Care Medicine. 1999;27(1):98–103.
    1. Erstad BL, Barletta JF, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. Crit Care. 1999;3(6):145–49.
    1. Barletta JF, Erstad BL, Fortune JB. Stress ulcer prophylaxis in trauma patients. Crit Care. 2002;6(6):526–30.
    1. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Critical Care Medicine. 2004;32(10):2008–13.
    1. Barletta JF, Kanji S, MacLaren R, Lat I, Erstad BL. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. Journal of Critical Care. 2014;29(6):955–60.
    1. Eastwood GM, Litton E, Bellomo R, Bailey MJ, Festa M, Beasley RW, et al. Opinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units. Critical Care and Resuscitation. 2014;16(3):170–4.
    1. Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, et al. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiologica Scandinavica. 2015;59(5):576–85.
    1. Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Critical Care Medicine. 2013;41(3):693–705.
    1. Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. The American Journal of Gastroenterology. 2012;107(4):507–20. quiz 21.
    1. Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nature Reviews. Gastroenterology & Hepatology. 2012;9(3):132–9.
    1. Krag M, Perner A, Wetterslev J, Wise MP, Hylander Moller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Medicine. 2014;40(1):11–22.
    1. MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Internal Medicine. 2014;174(4):564–74.
    1. Smith OM, McDonald E, Zytaruk N, Foster D, Matte A, Clarke F, et al. Enhancing the informed consent process for critical care research: strategies from a thromboprophylaxis trial. Intensive & Critical Care Nursing. 2013;29(6):300–9.
    1. Walker S, Iazzetta J, Law S. Extended stability of pantoprazole for injection in 0.9% sodium chloride or 5% dextrose at 4 degrees c and 23 degrees c. The Canadian Journal of Hospital Pharmacy. 2009;62(2):135–41.
    1. Donnelly RF. Stability of pantoprazole sodium in glass vials, polyvinyl chloride minibags, and polypropylene syringes. The Canadian Journal of Hospital Pharmacy. 2011;64(3):192–8.
    1. Dhaliwal R, Cahill N, Lemieux M, Heyland DK. The Canadian critical care nutrition guidelines in 2013: an update on current recommendations and implementation strategies. Nutrition in Clinical Practice. 2014;29(1):29–43.
    1. Smith OM, McDonald E, Zytaruk N, Foster D, Matte A, Clarke F, et al. Rates and determinants of informed consent: a case study of an international thromboprophylaxis trial. Journal of Critical Care. 2013;28(1):28–39.
    1. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. The American Journal of Managed Care. 2010;16(9):e228–34.
    1. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? The American Journal of Gastroenterology. 2003;98(1):51–8.
    1. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, et al. Dalteparin versus unfractionated heparin in critically ill patients. The New England Journal of Medicine. 2011;364(14):1305–14.
    1. Ego A, Preiser JC, Vincent JL. Impact of diagnostic criteria on the incidence of ventilator-associated pneumonia. Chest. 2015;147(2):347–55.
    1. Tejerina E, Esteban A, Fernandez-Segoviano P, Frutos-Vivar F, Aramburu J, Ballesteros D, et al. Accuracy of clinical definitions of ventilator-associated pneumonia: comparison with autopsy findings. Journal of Critical Care. 2010;25(1):62–8.
    1. Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary. Chest. 2000;117(4 Suppl 2):177S–81S.
    1. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. American Journal of Respiratory and Critical Care Medicine. 2000;162(2 Pt 1):505–11.
    1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) Infection Control and Hospital Epidemiology. 2010;31(5):431–55.
    1. Arnold DM, Lauzier F, Rabbat C, Zytaruk N, Barlow Cash B, Clarke F, et al. Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness. Thrombosis Research. 2013;131(3):204–9.
    1. Cook D, Walter S, Freitag A, Guyatt G, Devitt H, Meade M, et al. Adjudicating ventilator-associated pneumonia in a randomized trial of critically ill patients. Journal of Critical Care. 1998;13(4):159–63.
    1. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren